OncoSil Medical's Milestone in UK Clinical Study
OncoSil Medical Limited (ASX: $OSL) has achieved a significant milestone as the first patient in the UK was treated with the OncoSil device for the TRIPP-FXX clinical study, conducted at The Hammersmith Hospital in London.
Executive Commentary on Milestone Achievement
The first patient treatment using the OncoSil device for the TRIPP-FXX clinical study in the UK represents another significant step in our ongoing efforts to expand our label approval to include one of the backbone chemotherapies in combination with our device as a treatment option for patients with locally advanced pancreatic cancer.
It provides further proof that OncoSil Medical is successfully executing on two broad-based components of its overall growth strategy. The first of these is to continue our research of the OncoSil device through continued clinical studies. The second is to commercialise the device in several key target markets including Western Europe and the UK.
OncoSil Medical (ASX: $OSL) has marked a significant achievement with the first patient treatment using the OncoSil device for the TRIPP-FXX clinical study in the UK. The TRIPP-FXX study aims to assess the safety and efficacy of the OncoSil device when given with standard FOLFIRINOX chemotherapy for the treatment of locally advanced pancreatic cancer.
With 16-18 sites across Spain, the UK, Australia, Italy, and Belgium, the study has already recruited 29 patients. OncoSil Medical's CEO & Managing Director, Nigel Lange, emphasised the importance of this milestone, highlighting the company's commitment to expanding label approval and commercialising the device in key markets.
The OncoSil device has already received breakthrough device designation in the European Union, United Kingdom, and United States, and CE Marking for marketing in the European Union and United Kingdom.
